SCL Science Inc, formerly InnoTherapy Inc, is a Korea-based company principally engaged in the research, development, manufacture, export and sale of medical hemostatic agents. The main developed products include medical hemostats and sealants with biomimetic technology. In addition, the Company is engaged in the bio-logistics business.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
05/26/05	₩1,677.00	-1.99%	65,861
04/26/04	₩1,711.00	+4.39%	91,487
03/26/03	₩1,639.00	+1.67%	2,32,751
31/26/31	₩1,612.00	+9.21%	2,28,504
30/26/30	₩1,476.00	+2.50%	1,02,364

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Korea S.E. Other stock markets 05/08/2026			5-day change	1st Jan Change
1,677.00 ^KRW	-1.99%		+7.36%	-27.09%

15/05	SCL Science Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
23/03	SCL Science Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	5.7TCr 4.02Cr 3.47Cr 3.23Cr 2.98Cr 5.62Cr 381.64Cr 5.69Cr 38Cr 15Cr 190.8Cr 15Cr 15Cr 634.94Cr	P/E 2024	-16x	P/E 2025	-19.2x
Enterprise Value	7.96TCr 5.6Cr 4.85Cr 4.51Cr 4.16Cr 7.85Cr 532.39Cr 7.93Cr 53Cr 21Cr 266.17Cr 21Cr 21Cr 885.75Cr	EV / Sales 2024	13.3x	EV / Sales 2025	4.57x
Free-Float	45.72%	Yield 2024 *	-	Yield 2025	-

15/05	SCL Science Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
23/03	SCL Science Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
23/12	SCL Science Inc. agreed to acquire Bio-logistics business in Honam region of Seoul Clinical Laboratories for KRW 4.3 billion.	CI
14/11	SCL Science Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11/25/11	Scl Science to acquire 1.6 billion won worth of shares and majority stake in Pentamedix Co Ltd	RE
11/25/11	SCL Science Inc. agreed to acquire 60.31% stake in PentaMedix Co., Ltd. for KRW 1.6 billion.	CI
14/25/14	Scl Science wins 530 million won order	RE
14/25/14	SCL Science Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
28/25/28	SCL Science Inc. agreed to acquire Bio-logistics business in Yeongnam region of Seoul Clinical Laboratories from Seoul Clinical Laboratories for KRW 5.0 billion.	CI
15/25/15	SCL Science Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
31/25/31	SCL Science Inc. completed the acquisition of SCL Healthcare Co., Ltd.	CI
20/25/20	SCL Science Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
03/25/03	SCL Science Inc. announced that it has received KRW 14 billion in funding from a group of investors	CI

1 day	-1.99%
1 week	+7.36%
Current month	+4.03%
1 month	-1.29%
3 months	-15.86%
6 months	-21.82%
Current year	-27.09%

SCL Science Inc. Share Price

Stocks

A246960

KR7246960009

Pharmaceuticals

Valuation: SCL Science Inc.

Chart: SCL Science Inc.

Latest news : SCL Science Inc.

Quotes and Performance

Course Extremes

Managers and Directors: SCL Science Inc.

Latest insider transactions

Biopharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	1,429	1,750
1 month	1,389	1,946
Current year	1,389	2,680
1 year	1,389	3,250
3 years	1,389	5,110
5 years	1,389	5,110
10 years	1,300	6,950

Manager	Title	Age	Since
Kyung-Yul Lee CEO	Chief Executive Officer	-	28/12/2022
Se-Yeon Baek CEO	Chief Executive Officer	59	30/09/2024
Dae-Young Kim AUD	Comptroller/Controller/Auditor	63	28/12/2022

Director	Title	Age	Since
Se-Yeon Baek BRD	Director/Board Member	59	30/09/2024
Jeong-Gyun Choi BRD	Director/Board Member	59	30/09/2024
Kyung-Yul Lee BRD	Director/Board Member	-	28/12/2022

Date	Insider	Type	Main position	Quantity	% Market Cap.
11/08/25	Chang-ho Jin	Free		12,798	0.0377%
11/08/25	Se-Yeon Baek	Free	Chief Executive Officer	28,500	0.0840%
11/08/25	Han-Jo Kim	Free		1,359	0.0040%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SCL SCIENCE INC.	-1.99%	+7.36%	-38.57%	-18.69%	4.08Cr
REGENERON PHARMACEUTICALS, INC.	+1.04%	+10.56%	+34.48%	+0.28%	7.6TCr
UCB	+2.64%	-8.39%	+24.13%	+188.08%	4.9TCr
SAMSUNG BIOLOGICS CO.,LTD.	+1.02%	-3.74%	-7.47%	+21.83%	4.79TCr
CSL LIMITED	+1.42%	+9.32%	-50.68%	-50.72%	4.34TCr
BIOGEN INC.	-0.87%	+0.50%	+56.30%	-23.16%	3.08TCr
INCYTE CORPORATION	-0.66%	-7.80%	+53.51%	+88.28%	2.44TCr
MODERNA, INC.	-1.29%	+0.81%	+103.53%	-48.00%	2.28TCr
INNOVENT BIOLOGICS, INC.	+4.15%	+0.44%	-2.80%	+175.30%	1.92TCr
BRIDGEBIO PHARMA, INC.	-0.10%	-4.16%	+71.71%	+162.37%	1.6TCr
Average	+0.80%	+0.64%	+24.41%	+49.56%	3.3TCr
Weighted average by Cap.	+1.17%	+0.59%	+23.48%	+43.75%

	2024	2025
Net sales	473.71Cr 33.35L 28.85L 26.86L 24.78L 46.71L 32Cr 47.23L 3.16Cr 1.24Cr 16Cr 1.25Cr 1.22Cr 53Cr	2.2TCr 1.55Cr 1.34Cr 1.25Cr 1.15Cr 2.17Cr 147.26Cr 2.19Cr 15Cr 5.77Cr 74Cr 5.82Cr 5.69Cr 245Cr
Net income	-373.01Cr -26.26L -22.72L -21.15L -19.51L -36.78L -25Cr -37.19L -2.49Cr -97.77L -12Cr -98.55L -96.39L -42Cr	-393.43Cr -27.7L -23.96L -22.31L -20.58L -38.79L -26Cr -39.22L -2.63Cr -1.03Cr -13Cr -1.04Cr -1.02Cr -44Cr
Net Debt	314.54Cr 22.14L 19.16L 17.83L 16.45L 31.01L 21Cr 31.36L 2.1Cr 82.44L 11Cr 83.1L 81.28L 35Cr	2.25TCr 1.59Cr 1.37Cr 1.28Cr 1.18Cr 2.22Cr 150.75Cr 2.25Cr 15Cr 5.91Cr 75Cr 5.95Cr 5.82Cr 250.81Cr